AML: Mismatched unrelated donor with PTCy outscores CBT in absence of matched donors

Key clinical point: In the absence of human leukocyte antigen-matched donors, allogeneic hematopoietic cell transplantation (allo-HCT) using a mismatched unrelated donor (MMUD) with posttransplant cyclophosphamide (PTCy) yielded better survival outcomes vs. cord blood transplantation (CBT) in patients with acute myeloid leukemia (AML).

Major finding: CBT was associated with a significantly higher risk for nonrelapse mortality (adjusted hazard ratio [aHR], 2.09), worse leukemia-free survival (aHR, 1.68), and overall survival (aHR, 1.70) vs. MMUD (all P less than .0001).

Study details: This study included adult patients with AML who underwent a first allo-HCT using CBT (n=902) or single-allele MMUD with PTCy (n=280) between 2010 and 2019.

Disclosures: No funding source was disclosed. The authors declared no conflicts of interest.

Source: Dholaria B et al. J Hematol Oncol. 2021 May 3. doi: 10.1186/s13045-021-01086-2.

Key clinical point: In the absence of human leukocyte antigen-matched donors, allogeneic hematopoietic cell transplantation (allo-HCT) using a mismatched unrelated donor (MMUD) with posttransplant cyclophosphamide (PTCy) yielded better survival outcomes vs. cord blood transplantation (CBT) in patients with acute myeloid leukemia (AML).

Major finding: CBT was associated with a significantly higher risk for nonrelapse mortality (adjusted hazard ratio [aHR], 2.09), worse leukemia-free survival (aHR, 1.68), and overall survival (aHR, 1.70) vs. MMUD (all P less than .0001).

Study details: This study included adult patients with AML who underwent a first allo-HCT using CBT (n=902) or single-allele MMUD with PTCy (n=280) between 2010 and 2019.

Disclosures: No funding source was disclosed. The authors declared no conflicts of interest.

Source: Dholaria B et al. J Hematol Oncol. 2021 May 3. doi: 10.1186/s13045-021-01086-2.

Key clinical point: In the absence of human leukocyte antigen-matched donors, allogeneic hematopoietic cell transplantation (allo-HCT) using a mismatched unrelated donor (MMUD) with posttransplant cyclophosphamide (PTCy) yielded better survival outcomes vs. cord blood transplantation (CBT) in patients with acute myeloid leukemia (AML).

Major finding: CBT was associated with a significantly higher risk for nonrelapse mortality (adjusted hazard ratio [aHR], 2.09), worse leukemia-free survival (aHR, 1.68), and overall survival (aHR, 1.70) vs. MMUD (all P less than .0001).

Study details: This study included adult patients with AML who underwent a first allo-HCT using CBT (n=902) or single-allele MMUD with PTCy (n=280) between 2010 and 2019.

Disclosures: No funding source was disclosed. The authors declared no conflicts of interest.

Source: Dholaria B et al. J Hematol Oncol. 2021 May 3. doi: 10.1186/s13045-021-01086-2.